TY - JOUR
T1 - Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies
AU - Beran, M.
AU - Kantarjian, H. M.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Single-agent topotecan is an active drug in chemotherapy-naive MDS and CMML and, to a lesser degree, in refractory/relapsed acute leukemias, low-/intermediate-grade lymphoma, and myeloma. Its combination with cytosine arabinoside induces complete remissions in high-risk MDS/CMML. A triple-combination regimen of cyclophosphamide, cytosine arabinoside, and topotecan (CAT) was extensively tested in refractory/relapsed as well as in untreated AML. By proving effective in inducing complete remission in newly diagnosed AML at rates comparable to those achieved by anthracycline-cytosine arabinoside regimens, for example, CAT offers a useful treatment alternative. Topotecan combined with paclitaxel is promising in low-/intermediate-grade lymphomas. The activity of topotecan justifies further evaluation of topotecan-containing combination regimens, particularly in MDS/CMML and acute leukemias.
AB - Single-agent topotecan is an active drug in chemotherapy-naive MDS and CMML and, to a lesser degree, in refractory/relapsed acute leukemias, low-/intermediate-grade lymphoma, and myeloma. Its combination with cytosine arabinoside induces complete remissions in high-risk MDS/CMML. A triple-combination regimen of cyclophosphamide, cytosine arabinoside, and topotecan (CAT) was extensively tested in refractory/relapsed as well as in untreated AML. By proving effective in inducing complete remission in newly diagnosed AML at rates comparable to those achieved by anthracycline-cytosine arabinoside regimens, for example, CAT offers a useful treatment alternative. Topotecan combined with paclitaxel is promising in low-/intermediate-grade lymphomas. The activity of topotecan justifies further evaluation of topotecan-containing combination regimens, particularly in MDS/CMML and acute leukemias.
UR - http://www.scopus.com/inward/record.url?scp=0034517204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034517204&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2000.tb07043.x
DO - 10.1111/j.1749-6632.2000.tb07043.x
M3 - Article
C2 - 11193900
AN - SCOPUS:0034517204
SN - 0077-8923
VL - 922
SP - 247
EP - 259
JO - Annals of the New York Academy of Sciences
JF - Annals of the New York Academy of Sciences
ER -